Axial Therapeutics

Clinical-stage biopharmaceutical company focused on developing gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. Axial Therapeutics leverages groundbreaking microbiome science to address various diseases and disorders, including autism, differentiating itself through its unique approach to targeting the gut-brain axis. The company's primary target demographic includes patients suffering from CNS disorders and related conditions.